Pharmaceutical

Theseus terminates its GI cancer drug development programme

Theseus Pharmaceuticals has terminated its pan-variant tyrosine kinase receptor (KIT) inhibitor (THE-630) drug development programme.

Jul 15, 2023 - 20:00
Theseus terminates its GI cancer drug development programme
Theseus Pharmaceuticals has terminated its pan-variant tyrosine kinase receptor (KIT) inhibitor (THE-630) drug development programme.
Read the original article

Tags:

Previous Article

CureVac turns up the heat in ongoing patent litigation with Pfizer

Next Article

Vistagen obtains Canadian Notice of Allowance for AV-101 patent

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

No one’s pleased with the government’s pitch for 2025 Medicare Advantage rates

No one’s pleased with the government’s pitch for 2025 M...

Feb 13, 2024

STAT+: Digital health pioneer Pear Therapeutics files for bankruptcy

STAT+: Digital health pioneer Pear Therapeutics files f...

Apr 7, 2023

STAT+: Data backing prescription digital therapeutics found lacking in rigor, inclusivity

STAT+: Data backing prescription digital therapeutics f...

Nov 7, 2023